| CTRI Number |
CTRI/2024/12/077795 [Registered on: 06/12/2024] Trial Registered Prospectively |
| Last Modified On: |
05/05/2026 |
| Post Graduate Thesis |
Yes |
| Type of Trial |
Interventional |
|
Type of Study
|
Drug |
| Study Design |
Randomized, Parallel Group, Active Controlled Trial |
|
Public Title of Study
|
Methylene Blue as an early treatment for septic shock |
|
Scientific Title of Study
|
Methylene Blue as an early Adjunctive treatment for septic shock-A
Randomized Controlled Trial |
| Trial Acronym |
|
|
Secondary IDs if Any
|
| Secondary ID |
Identifier |
| NIL |
NIL |
|
|
Details of Principal Investigator or overall Trial Coordinator (multi-center study)
|
| Name |
Dr Rishwanth Raja P M |
| Designation |
Postgraduate |
| Affiliation |
Sri Ramachandra Institute of Higher Education and Research |
| Address |
G Block 1st Floor Department of critical care medicine Sri
Ramachandra Institute of Higher Education and Research No 1
Ramachandra Nagar Porur Chennai 600116 Tamil Nadu India
Thiruvallur TAMIL NADU 600116 India |
| Phone |
8870767379 |
| Fax |
|
| Email |
rishwanthraja123@gmail.com |
|
Details of Contact Person Scientific Query
|
| Name |
Dr Renuka M K |
| Designation |
Professor |
| Affiliation |
Sri Ramachandra Institute of Higher Education and Research |
| Address |
G Block 1st Floor Department of critical care medicine Sri
Ramachandra Institute of Higher Education and Research No 1
Ramachandra Nagar Porur Chennai 600116 Tamil Nadu India
Thiruvallur TAMIL NADU 600116 India |
| Phone |
8056126336 |
| Fax |
|
| Email |
hod.criticalcare@sriramachandra.edu.in |
|
Details of Contact Person Public Query
|
| Name |
Dr Rishwanth Raja P M |
| Designation |
Postgraduate |
| Affiliation |
Sri Ramachandra Institute of Higher Education and Research |
| Address |
G Block 1st Floor Department of critical care medicine Sri
Ramachandra Institute of Higher Education and Research No 1
Ramachandra Nagar Porur Chennai 600116 Tamil Nadu India
Thiruvallur TAMIL NADU 600116 India |
| Phone |
8870767379 |
| Fax |
|
| Email |
rishwanthraja123@gmail.com |
|
|
Source of Monetary or Material Support
|
| Sri Ramachandra Institute of Higher Education and Research No 1 Ramachandra Nagar Porur Chennai 600116 Tamil Nadu India |
|
|
Primary Sponsor
|
| Name |
DR RISHWANTH RAJA P M |
| Address |
G Block 1st floor Department of Critical Care Medicine Sri Ramachandra Institute of Higher Education and Research No 1 Ramachandra Nagar Porur Chennai 600116 Tamil Nadu India |
| Type of Sponsor |
Other [Self] |
|
|
Details of Secondary Sponsor
|
|
|
Countries of Recruitment
|
India |
|
Sites of Study
|
| No of Sites = 1 |
| Name of Principal
Investigator |
Name of Site |
Site Address |
Phone/Fax/Email |
| Dr Rishwanth Raja P M |
Sri Ramachandra Institute of Higher Education and Research |
G Block 1st floor Room number 09
Department of critical care medicine
Sri Ramachandra Institute of Higher Education and Research
Number 01 ramachandra nagar
Porur Chennai -600116
Thiruvallur TAMIL NADU |
8870767379
rishwanthraja123@gmail.com |
|
|
Details of Ethics Committee
|
| No of Ethics Committees= 1 |
| Name of Committee |
Approval Status |
| Institutional Ethics Committee Sri Ramachandra Institute of Higher Education and Research Porur Chennai 600116 |
Approved |
|
|
Regulatory Clearance Status from DCGI
|
|
|
Health Condition / Problems Studied
|
| Health Type |
Condition |
| Patients |
(1) ICD-10 Condition: I998||Other disorder of circulatory system, |
|
|
Intervention / Comparator Agent
|
| Type |
Name |
Details |
| Intervention |
METHYLENE BLUE |
In septic shock patients, when Norepinephrine dose reached 0.20 mcg/kg/min, Vasopressin is initiated at 0.03IU/min, methylene blue is administered after test dose along with vasopressin, intravenous administration with dosing regimen Bolus of 2mg/kg is given followed by infusion of 0.25mg/kg/h in 0.9% sodium chloride solution for 6 hours given for two consecutive days. Tapering of vasopressors at periodic intervals is followed accordingly. |
| Comparator Agent |
Vasopressors |
The standard protocol of treatment of septic shock is initiated with vasopressors when Norepinephrine dose reached 0.20 mcg/kg/min, Vasopressin is initiated at 0.03IU/min followed by initiation of epinepherine in standard group, Physician-led vasopressor tapering protocol ofnorepinephrine, vasopresssin, epinephrine titration at 15–20min intervals to maintain mean arterial pressure (MAP- 70 mmHg) will be continued. |
|
|
Inclusion Criteria
|
| Age From |
18.00 Year(s) |
| Age To |
80.00 Year(s) |
| Gender |
Both |
| Details |
1)Age greater than 18 years,
2)Highly suspected or confirmed infection
3)Norepinephrine dose greater than 0.2mcg/kg/min to maintain MAP greater than 65 mmHg
4)Less than 6 hrs of starting noradrenaline
|
|
| ExclusionCriteria |
| Details |
1)Pregnancy
2)Chronic kidney disease
3)Concurrent hemorrhagic, obstructive, cardiogenic, hypovolemic shock,
4)Greater than 24 hours of septic shock,
History of glucose-6-phosphate dehydrogenase deficiency,
5)Allergy to methylene blue
6)Drug interactions: Phenothiazines, selective serotonin re-uptake inhibitors, Dapsone
7)Refusal of the patient or decision maker to participate.
|
|
|
Method of Generating Random Sequence
|
Computer generated randomization |
|
Method of Concealment
|
On-site computer system |
|
Blinding/Masking
|
Open Label |
|
Primary Outcome
|
| Outcome |
TimePoints |
| To assess whether early adjunctive Methylene blue can reduce time to vasopressor discontinuation in patients with septic shock |
7 days 14 days 21days |
|
|
Secondary Outcome
|
| Outcome |
TimePoints |
| To assess the effects of continuous infusion of methylene blue on cardiac & renal SOFA scores, serum lactate levels |
24 hours 48 hours 72 hours |
|
|
Target Sample Size
|
Total Sample Size="120" Sample Size from India="120"
Final Enrollment numbers achieved (Total)= "Applicable only for Completed/Terminated trials"
Final Enrollment numbers achieved (India)="Applicable only for Completed/Terminated trials" |
|
Phase of Trial
|
Phase 4 |
|
Date of First Enrollment (India)
|
11/12/2024 |
| Date of Study Completion (India) |
Applicable only for Completed/Terminated trials |
| Date of First Enrollment (Global) |
Date Missing |
| Date of Study Completion (Global) |
Applicable only for Completed/Terminated trials |
|
Estimated Duration of Trial
|
Years="2" Months="0" Days="0" |
Recruitment Status of Trial (Global)
Modification(s)
|
Not Applicable |
| Recruitment Status of Trial (India) |
Open to Recruitment |
|
Publication Details
|
N/A |
|
Individual Participant Data (IPD) Sharing Statement
|
Will individual participant data (IPD) be shared publicly (including data dictionaries)?
Response - NO
|
|
Brief Summary
|
Patient selection: Patients aged >18yrs who are highly suspected or confirmed infection, the patients will be checked for volume responsiveness by straight leg rise and capillary refill time after adequate fluid resuscitation with 500ml bolus of balanced crystalloid, if found to have negative response. Patients are initiated on Norepinephrine to maintain MAP>65 mmHg, Patients are selected if time to vasopressor initiation <6hrs. All the components in exclusion criteria will be assessed before eligibility. Randomisation, Intervention, Measurements: After informed consent the patients are randomized 1:1 to methylene blue group or the standard group by computer generated simple randomization. Both the groups will continue to get similar standard of care according to protocol. When Norepinephrine dose reached >0.20 mcg/kg/min, Vasopressin is initiated at 0.03IU/min in both groups. In the Methylene blue group, after test dose, the dosing regimen - Bolus of 2mg/kg followed by infusion of 0.25mg/kg/h in 0.9%Nacl solution for 6hrs for two consecutive days. Physician-led vasopressor tapering protocol of norepinephrine titration at 15–20min intervals to maintain mean arterial pressure (MAP-70 mmHg) will be continued. Our standard protocol calls for the initiation of epinephrine, even after reaching the maximum dose requirement for dual vasopressors. Weaning of vasopressors will also be according to periodic intervals by withdrawal epinephrine followed by vasopressin and norepinephrine. Close monitoring of meth-hemoglobin levels will be done periodically to avoid complications. Hydrocortisone at 50mg Q6hrly dose is also a standard in our unit,will be initiated and it is withheld after 24-h after discontinuation of all vasopressors. |